Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT07624734

Impact of the Intraoperative Use of Amines in Breast Cancer Surgery on Tumor Recurrence

Adrenergic receptors (alpha and beta) are expressed on breast cancer cells, and their stimulation has been shown in experimental studies to promote tumor proliferation and metastasis. Conversely, observational data suggest that beta-blockers may have a protective effect on cancer recurrence. During mastectomy, adrenergic agonists such as catecholamines (e.g., ephedrine, phenylephrine, norepinephrine) and other agents (e.g., clonidine) are frequently used intraoperatively to maintain hemodynamic stability, potentially activating these receptors. While some data suggest that perioperative adrenergic stimulation may influence tumor biology, the clinical impact on cancer recurrence remains unclear.

This retrospective exploratory study aims to evaluate whether the use of adrenergic agents during anesthesia for mastectomy influences tumor recurrence in breast cancer patients. Approximately 250 patients undergoing mastectomy over a 5-year period will be included. The study will assess the association between intraoperative exposure to adrenergic drugs and oncological outcomes, with the goal of better understanding the potential role of perioperative factors in cancer progression.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Sex eligibility

All sexes

Study type

Observational

Primary location

CHU Montpellier

Montpellier, Hérault, 34000, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • patients operated for a mastectomy for breast cancer

Exclusion criteria

  • other surgeries for breast cancer not being a mastectomy
  • mastectomy for other conditions than cancer

Treatment and study plan

collection of health data from electronic medical records

Other

collection of demographic data, key medical history, use of beta-blockers prior to surgery, anesthesia-related data (agents used to maintain anesthesia, regional anesthesia in addition to general anesthesia, intraoperative use of amines), postoperative morphine consumption, survival, and cancer recurrence within 5 years post-surgery

Primary outcomes

  1. cancer recurrence

    Time frame: 5 years post-surgery

    either local recurrence or metastases

Sponsors and collaborators

Lead sponsor

University Hospital, Montpellier

Other

Registry information

Acronym: MASTECTAMINE

Important dates

Study start
2025
Primary completion
2026
Study completion
2027
First posted
Jun 3, 2026
Registry last updated
Jun 3, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.